# P1 V7 Phase 2 Progress Report

**Date:** 2026-01-11  
**Phase:** V4 Resource Integration  
**Status:** IN PROGRESS (2/7 tables complete)

---

## ✅ COMPLETED TASKS

### 1. Physicochemical Properties Table ✅

**Script:** `scripts/v7_generate_physicochemical_table.py`  
**Output CSV:** `results/derived/v7_physicochemical_properties.csv`  
**Output LaTeX:** `manuscript/tables/sm_table_physicochemical.tex`

**Key Findings:**
- All 17 candidates processed successfully
- Mean MW: 271.9 ± 69.3 Da (range: 164.2 - 388.5)
- Mean logP: 2.84 ± 0.82 (range: 1.49 - 4.40)
- Mean TPSA: 66.3 ± 29.4 ų (range: 15.8 - 113.3)
- Mean QED: 0.703 ± 0.063 (range: 0.600 - 0.802)
- **All 17 candidates have 0 Lipinski violations** ✓

**Table Contents:**
- Columns: Candidate, MW, logP, HBD, HBA, TPSA, RB, fsp³, QED, SA, Lipinski violations
- 17 data rows + 1 summary row (mean values)
- Ready for insertion into V7 SM

### 2. Drug-Likeness Compliance Table ✅

**Script:** `scripts/v7_generate_druglikeness_table.py`  
**Output CSV:** `results/derived/v7_druglikeness_compliance.csv`  
**Output LaTeX:** `manuscript/tables/sm_table_druglikeness.tex`

**Key Findings:**
- **Lipinski Rule of 5:** 17/17 pass (100.0%)
- **Veber Rules:** 17/17 pass (100.0%)
- **QED High (>0.70):** 8/17 (47.1%)
- **NP-relatedness (NPL>0):** 16/17 (94.1%)
- **Overall Full Compliance:** 8/17 (47.1%)

**Table Contents:**
- Columns: Candidate, Lipinski, Veber, QED, QED Value, NPL, NPL Value, Overall
- 17 data rows + 2 summary rows (counts and percentages)
- Uses checkmark/cross symbols for pass/fail
- Ready for insertion into V7 SM

---

## 🔄 REMAINING TASKS

### 3. ADMET Profile Table (Priority: High)

**Target:** SM Table S6  
**Status:** ⏳ PENDING

**Data Needed:**
- CYP450 inhibition (CYP2C9, CYP2C19, CYP3A4, CYP2D6)
- hERG blocking potential
- Drug-Induced Liver Injury (DILI) risk
- Selectivity Index (SI_pred)

**Action Plan:**
1. Check BMAD for Set-C ADMET data (grep "CYP|hERG|DILI" + "PP-")
2. If missing, run ADMET-AI predictions on 17 SMILES
3. Generate LaTeX table with ADMET profile
4. Insert into V7 SM

### 4. Scaffold Analysis Table (Priority: Medium)

**Target:** SM Table S7  
**Status:** ⏳ PENDING

**Data Needed:**
- Bemis-Murcko scaffolds for each candidate
- Tanimoto similarity to nearest seed NP
- NP-relatedness classification (Tanimoto ≥ 0.4)
- Scaffold diversity metrics

**Action Plan:**
1. Extract Bemis-Murcko scaffolds from SMILES
2. Calculate Tanimoto to ANPDB seed compounds
3. Generate LaTeX table with scaffold analysis
4. Insert into V7 SM

### 5. Stage-Specific Activity Table (Priority: Medium)

**Target:** SM Table S8  
**Status:** ⏳ PENDING

**Data Needed:**
- eos80ch predictions (asexual vs sexual stage activity)
- Stage preference classification

**Action Plan:**
1. Check BMAD for Set-C eos80ch predictions
2. If missing, run Ersilia eos80ch model on 17 SMILES
3. Generate LaTeX table with stage activity
4. Insert into V7 SM

### 6. Binding Mode Figures (Priority: Critical)

**Target:** SM Figure (interaction diagrams)  
**Status:** ⏳ PENDING

**Data Needed:**
- Docking pose files (PDBQT or PDB) for PP-01 to PP-17
- Protein-ligand interaction profiles

**Action Plan:**
1. Search V5/V6/V7 results for pose files
2. If found, generate 2D interaction diagrams (PyMOL/LigPlot+)
3. Create multi-panel figure (17 subpanels or grouped by target)
4. Insert into V7 SM

### 7. Main Text Enhancements (Priority: High)

**Introduction:**
- Add accessibility gap argument (1000 CPU-hours, 94% endemic regions)
- Strengthen hybrid NP+SD rationale

**Methods:**
- Add grid box specifications for all 4 targets
- Add brief centroid-based sampling background

**Results:**
- Add named lead analysis (PP-06, PP-11, PP-15)
- Use V4 ligand 201/214/438 format as template

**Discussion:**
- Add computational efficiency context (99.3% reduction)
- Add activity cliff discussion
- Add literature positioning (ANPDB coverage)

---

## 📊 PROGRESS METRICS

### Tables Completed: 2/7 (28.6%)

- ✅ SM Table S4: Physicochemical Properties
- ✅ SM Table S5: Drug-Likeness Compliance
- ⏳ SM Table S6: ADMET Profile (pending data check)
- ⏳ SM Table S7: Scaffold Analysis (pending script)
- ⏳ SM Table S8: Stage-Specific Activity (pending data check)
- ✅ SM Table S1: Vina Affinity Matrix (already in V7 SM)
- ✅ SM Table S2-S3: RRS/Correlations (already in V7 SM)

### Figures Completed: 0/1 (0%)

- ⏳ SM Figure: Binding mode interaction diagrams (pending pose file search)

### Main Text Enhancements: 0/4 (0%)

- ⏳ Introduction enhancement
- ⏳ Methods enhancement
- ⏳ Results named lead analysis
- ⏳ Discussion expansion

---

## ⏱️ ESTIMATED TIME REMAINING

### Must-Have Tasks (Day 1-2):
- **Insert tables into V7 SM:** 30 min ✅ NEXT
- **ADMET data extraction/generation:** 2-4 hours
- **Scaffold analysis script + table:** 2-3 hours
- **Main text enhancements:** 3-4 hours
- **Compilation and cross-reference checks:** 1 hour

**Subtotal:** ~8-12 hours remaining

### Nice-to-Have Tasks (Day 3):
- **Stage activity data/table:** 2-3 hours
- **Binding mode figure search + generation:** 4-8 hours (if poses available)

**Subtotal:** ~6-11 hours additional

---

## 🎯 NEXT IMMEDIATE ACTION

**Task:** Insert completed tables into V7 SM

**Steps:**
1. Read current V7 SM to find insertion point for tables
2. Insert SM Table S4 (physicochemical properties)
3. Insert SM Table S5 (drug-likeness compliance)
4. Update table numbering and cross-references
5. Compile V7 to verify 0 errors

**Estimated Time:** 30 minutes

---

## 📈 SUCCESS CRITERIA

### Phase 2 Complete When:
- ✅ SM has physicochemical properties table
- ✅ SM has drug-likeness compliance table
- ⏳ SM has ADMET table (or note "not available")
- ⏳ SM has scaffold analysis table
- ⏳ Main Introduction has accessibility argument
- ⏳ Main Discussion has V4 efficiency context
- ⏳ Main Discussion has named lead analysis
- ⏳ All tables cross-referenced in text
- ⏳ Manuscript compiles with 0 errors

### Current Completion: 28.6% (2/7 tables)

---

## 💡 KEY INSIGHTS

1. **Excellent drug-likeness profile:** 100% Lipinski/Veber compliance, mean QED 0.703
2. **Strong NP-relatedness:** 94.1% have NPL > 0 (16/17 candidates)
3. **Favorable physicochemistry:** All candidates well within drug-like space
4. **Ready for JCIM submission:** Tables are publication-quality with proper formatting

---

**STATUS:** ✅ ON TRACK - Proceeding to table insertion

